You have accessJournal of UrologyCME1 May 2022MP23-06 NEOADJUVANT CHEMOTHERAPY BEFORE RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER: PATIENT, PROVIDER, AND CLINICAL ETIOLOGIES FOR LACK OF UTILIZATION Hiten D. Patel, Ushasi Naha, Victor S. Chen, Caitlyn Ko, Rachel Yang, Aleksander Druck, Goran Rac, and Marcus L. Quek Hiten D. PatelHiten D. Patel More articles by this author , Ushasi NahaUshasi Naha More articles by this author , Victor S. ChenVictor S. Chen More articles by this author , Caitlyn KoCaitlyn Ko More articles by this author , Rachel YangRachel Yang More articles by this author , Aleksander DruckAleksander Druck More articles by this author , Goran RacGoran Rac More articles by this author , and Marcus L. QuekMarcus L. Quek More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002562.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Neoadjuvant chemotherapy (NAC) represents a standard of care prior to radical cystectomy for muscle-invasive bladder cancer (MIBC; ≥cT2). While NAC utilization has increased over time in the United States, many patients may not receive NAC due to reasons that are difficult to identify in administrative or registry data. We aimed to assess utilization of NAC and etiologies for lack of NAC receipt among consecutive patients at a single institution. METHODS: Patients diagnosed with bladder cancer and undergoing radical cystectomy at Loyola University Medical Center (2005-2021) were included. Clinical variables included age, sex, race, comorbidities, prior intravesical therapy, hydronephrosis, histology, clinical stage, and surgical approach. Patients were categorized by stage and receipt of NAC. Early and recent time periods were evaluated among all ≥cT2 patients and after exclusion of non-candidates. Reasons for no NAC were categorized. Overall survival (OS) was evaluated with Kaplan-Meier curves and multivariable Cox proportional hazards regression models. RESULTS: Of 589 evaluable patients, 380 (64.5%) had ≥cT2 disease and 209 (35.5%) <cT2. Among ≥cT2 patients, a total of 155 (40.8%) received NAC with significant increase in utilization from the early to recent time periods (22.8% to 67.8%, p <0.001). Utilization of NAC was similar for open and robotic approach (p=0.15). Among 225 patients not receiving NAC, reasons included renal dysfunction (28.0%), patient symptoms (9.3%), concern for disease progression (8.4%), salvage setting (3.1%), patient preference/refusal (24.4%), and provider recommendation (26.7%). Provider recommendation was related to comorbidities (18/60 (30.0%); e.g. prior chemotherapy, hearing loss, non-renal comorbidity), histology (20/60 (33.3%); e.g. squamous or adenocarcinoma histology), or not mentioned (22/60 (36.7%)). After excluding non-candidates for NAC, increase in utilization from the early to recent time periods was 34.2% to 85.8% (p <0.001). Patient preference/refusal decreased from 29.0% to 8.2% in the early to recent time periods (p <0.001). NAC was associated with improved OS (HR 0.54, p=0.003). Patients with reasons to forgo NAC had worse OS including due to renal dysfunction (HR 1.98, p=0.007), symptoms (HR 2.27, p=0.03), or provider recommendation (HR 2.35, p=0.002). CONCLUSIONS: NAC utilization increased over time with change in estimates before and after exclusion of non-candidates. Renal dysfunction, patient preference, and provider recommendation based on histologic or clinical concerns were primary etiologies for lack of NAC prior to radical cystectomy for muscle-invasive bladder cancer. Fewer patients refused NAC in recent years leading to a potential ceiling for NAC utilization. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e383 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hiten D. Patel More articles by this author Ushasi Naha More articles by this author Victor S. Chen More articles by this author Caitlyn Ko More articles by this author Rachel Yang More articles by this author Aleksander Druck More articles by this author Goran Rac More articles by this author Marcus L. Quek More articles by this author Expand All Advertisement PDF downloadLoading ...
Read full abstract